½ÃÀ庸°í¼­
»óǰÄÚµå
1587151

¼¼°èÀÇ ÀÓ»ó À§Çè ±×·ìÈ­ ¼Ö·ç¼Ç ½ÃÀå : Á¦Ç°, µµÀÔ ÇüÅÂ, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)

Clinical Risk Grouping Solution Market by Product (Dashboard Analytics Solutions, Risk Reporting Solutions, Scorecards & Visualization Tools), Deployment Mode (Private Cloud, Public Cloud), End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 197 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÀÓ»ó À§Çè ±×·ìÈ­ ¼Ö·ç¼Ç ½ÃÀåÀº 2023³â¿¡ 9¾ï 2,517¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 10¾ï 5,219¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2030³â¿¡´Â 22¾ï 8,995¸¸ ´Þ·¯±îÁö 13.82%ÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÓ»ó À§Çè ±×·ìÈ­ ¼Ö·ç¼Ç(CRGS) ½ÃÀåÀº ÀÓ»ó À§Çè ÇÁ·ÎÆÄÀÏÀ» ±â¹ÝÀ¸·Î ȯÀÚ¸¦ ºÐ·ùÇϱâ À§ÇØ °í¾ÈµÈ °í±Þ µµ±¸ °³¹ß¿¡ ÁßÁ¡À» µÐ ºÎ¹®ÀÔ´Ï´Ù. CRGSÀÇ ÁÖ¿ä ¹üÀ§´Â °³ÀÎÈ­ µ¥ÀÌÅÍ ±â¹Ý ÄÉ¾î °ü¸®¸¦ °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á °Ç°­ °ü¸®ÀÇ ¼º°ú¸¦ ³ôÀÌ´Â °ÍÀÔ´Ï´Ù. µû¶ó¼­ ÀÇ·á ½Ç¼ö¸¦ ÁÙÀÔ´Ï´Ù. ÀÇ·áºñ¸¦ Àý°¨Çϰí ȯÀÚÀÇ °á°ú¸¦ °³¼±Çϱâ À§ÇØ ÇʼöÀûÀÔ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. Àº °Ç°­ °ü¸®¿¡¼­ µ¥ÀÌÅÍ ºÐ¼®ÀÇ µµÀÔ Áõ°¡, ÄɾîÀÇ Áú°ú È¿À²¼ºÀÇ Á߽à Áõ°¡, ȯÀÚ ÄɾîÀÇ ¿ä±¸ÀÇ º¹ÀâÈ­ÀÔ´Ï´Ù. ¼ö¿ä¸¦ ´õ¿í ¹Ð¾îÁÝ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 9¾ï 2,517¸¸ ´Þ·¯
¿¹Ãø³â(2024) 10¾ï 5,219¸¸ ´Þ·¯
¿¹Ãø³â(2030) 22¾ï 8,995¸¸ ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 13.82%

ÃֽŠÀáÀç ±âȸ´Â CRGSÀÇ ¿¹Ãø Á¤È®¼º°ú È¿À²¼ºÀ» ³ôÀÌ´Â AI ¹× ¸Ó½Å·¯´×°ú °°Àº ±â¼úÀû Áøº¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù ¶ÇÇÑ ½ÅÈï ½ÃÀå¿¡ ÁøÃâÀºÀÌ Áö¿ªÀÇ °Ç°­ °ü¸® ½Ã½ºÅÛÀÇ µðÁöÅÐ º¯È­¿¡ Çâ»óµÇ°í ¼ºÀåÀÇ ¶Ç ´Ù¸¥ ±æÀ» º¸¿©ÁÝ´Ï´Ù. ±×·¯³ª °í°¡ÀÇ µµÀÔ ºñ¿ë, µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã¿¡ ´ëÇÑ ¿ì·Á, ±âÁ¸ÀÇ °Ç°­ °ü¸® IT »ýŰ迡 ¸ÂÃß´Â µ¥ ÇÊ¿äÇÑ ¹Ì¹¦ÇÑ ÅëÇÕ°ú °°Àº ¹®Á¦´Â ¿©ÀüÈ÷ ³²¾Æ ÀÖ½À´Ï´Ù. ¶ÇÇÑ º¯È­¿¡ ´ëÇÑ ÀúÇ×°¨°ú ÀÇ·á Á¾»çÀÚÀÇ ½ºÅ³ °¸ÀÌ ¿øÈ°ÇÑ µµÀÔÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù.

Çõ½Å ±âȸ´Â ÃÖ¼ÒÇÑÀÇ ±³À°À¸·Î ³¡³ª´Â »ç¿ëÀÚ Ä£È­Àû ÀÎ ÀÎÅÍÆäÀ̽º °³¹ß°ú Ç÷§Æû °£ÀÇ ¿øÈ°ÇÑ µ¥ÀÌÅÍ È帧À» º¸ÀåÇϱâÀ§ÇÑ »óÈ£ ¿î¿ë¼º Ç¥ÁØÀ» °³¼±ÇÏ´Â µ¥ ÀÖ½À´Ï´Ù. ±³Â÷ ÀÌ Á¡À» ¹Ý¿µÇÏ°í °í°´ÀÇ Çǵå¹é°ú ±â¼ú Áøº¸·Î Áö¼ÓÀûÀÎ Çõ½ÅÀÌ °æÀï·ÂÀ» À¯ÁöÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ÇÏ´Â ½ÃÀå »óȲ¸¦ Ȱ¿ëÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ À־ ÇʼöÀûÀÔ´Ï´Ù.

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ÀÓ»ó À§Çè, ±×·ìÈ­ ¼Ö·ç¼Ç ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ÀÓ»ó ¸®½ºÅ© ±×·ìÇÎ ¼Ö·ç¼Ç ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿Àû ÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯È­¸¦ °Þ°í ÀÖ½À´Ï´Ù. ÀÇ»ç °áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ÀÌ´Â Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ´õ¿í ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ȯÀÚÀÇ ¸®½ºÅ© °ü¸®¿¡ ´ëÇÑ ÁÖ¸ñ Áõ°¡
    • ÇコÄÉ¾î ¾÷°è¿¡¼­ÀÇ ºòµ¥ÀÌÅÍ µµÀÔ¿¡ ÀÇÇÑ ÀÓ»ó °á°úÀÇ º¯È­
    • ¸®½ºÅ© °ü¸® ¼Ö·ç¼ÇÀÇ ÀåÁ¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÀÚº» Áý¾àÀûÀÎ ÀÓ»ó ¼Ö·ç¼Ç°ú ÇÔ²² ÀÎÇÁ¶óÀÇ ºÎÁ·
  • ½ÃÀå ±âȸ
    • AI¿Í ¸Ó½Å·¯´×¿¡ ´ëÇÑ ÁÖ¸ñ Áõ°¡
    • °Ç°­ ±â·ÏÀÇ ±â·Ï°ú À¯Áö º¸±Þ
    • ¹®¼­È­ÀÇ Çʿ伺¿¡ ÀÇÇÑ ÀÇ»çÀÇ ºÒŸ´Â ÁõÈıº Áõ°¡
  • ½ÃÀåÀÇ °úÁ¦
    • ȯÀÚ µ¥ÀÌÅÍÀÇ ÇÁ¶óÀ̹ö½Ã¿¡ °üÇÑ ¿ì·Á

Porter's Five Forces : ÀÓ»ó À§Çè ±×·ìÇÎ ¼Ö·ç¼Ç ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ´ç½ÅÀº ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÀÓ»ó À§Çè ±×·ìÇÎ ¼Ö·ç¼Ç ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÀÓ»ó À§Çè ±×·ìÈ­ ¼Ö·ç¼Ç ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÀÓ»ó À§Çè, ±×·ìÈ­ ¼Ö·ç¼Ç ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

ÀÓ»ó À§Çè ±×·ìÈ­ ¼Ö·ç¼Ç ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­ ¹× ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í °ø±Þ¾÷ü´Â °æÀïÀÌ Ä¡¿­ÇØÁö¸é¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ÀÓ»ó À§Çè ±×·ìÇÎ ¼Ö·ç¼Ç ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÀÓ»ó À§Çè ±×·ìÇÎ ¼Ö·ç¼Ç ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÎ¹®È­Çϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå ÀÓ»ó À§Çè, ±×·ìÈ­ ¼Ö·ç¼Ç ½ÃÀå¿¡¼­ ¼º°øÀÇ ±æÀ» ±×¸³´Ï´Ù.

ÀÓ»ó ¸®½ºÅ© ±×·ìÇÎ ¼Ö·ç¼Ç ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÎ¹®¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÎ¹®ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ, ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ȯÀÚÀÇ ¸®½ºÅ© °ü¸®¿¡ ÁßÁ¡È­
      • ÇコÄÉ¾î ¾÷°è¿¡¼­ÀÇ ºòµ¥ÀÌÅÍ µµÀÔ¿¡ ÀÇÇÑ ÀÓ»ó °á°úÀÇ º¯È­
      • ¸®½ºÅ© °ü¸® ¼Ö·ç¼ÇÀÇ ÀåÁ¡
    • ¾ïÁ¦¿äÀÎ
      • ÀÎÇÁ¶ó ºÎÁ·°ú ÀÚº» Áý¾àÀûÀÎ ÀÓ»ó ¼Ö·ç¼Ç
    • ±âȸ
      • AI¿Í ¸Ó½Å·¯´×¿¡ ´ëÇÑ ÁÖ¸ñÀÌ ³ô¾ÆÁø´Ù
      • °Ç°­ ±â·ÏÀÇ ±â·Ï°ú À¯ÁöÀÇ µµÀÔ
      • ¹®¼­ ÀÛ¼ºÀÇ Çʿ伺¿¡ ÀÇÇÑ ÀÇ»çÀÇ ÇÇÆó Áõ°¡
    • °úÁ¦
      • ȯÀÚ µ¥ÀÌÅÍÀÇ ÇÁ¶óÀ̹ö½Ã¿¡ °üÇÑ ¿ì·Á
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ÀÓ»ó À§Çè ±×·ìÈ­ ¼Ö·ç¼Ç ½ÃÀå : Á¦Ç°º°

  • ´ë½Ãº¸µå ºÐ¼® ¼Ö·ç¼Ç
  • À§Ç躸°í ¼Ö·ç¼Ç
  • ½ºÄÚ¾î Ä«µå ¹× ½Ã°¢È­ µµ±¸

Á¦7Àå ÀÓ»ó À§Çè ±×·ìÈ­ ¼Ö·ç¼Ç ½ÃÀå : Àü°³ ¸ðµåº°

  • ÇÁ¶óÀ̺ø Ŭ¶ó¿ìµå
  • ÆÛºí¸¯ Ŭ¶ó¿ìµå

Á¦8Àå ÀÓ»ó À§Çè, ±×·ìÈ­ ¼Ö·ç¼Ç ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ¿Ü·¡ Áø·á ¼¾ÅÍ
  • º´¿ø
  • Àå±â ÄÉ¾î ¼¾ÅÍ
  • ÁöºÒÀÚ

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ÀÓ»ó À§Çè, ±×·ìÇÎ ¼Ö·ç¼Ç ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÓ»ó À§Çè, ±×·ìÈ­ ¼Ö·ç¼Ç ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÓ»ó À§Çè, ±×·ìÇÎ, ¼Ö·ç¼Ç ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • 3M Company
  • Conduent, Inc.
  • Dynamic Healthcare Systems, Inc. by Reveleer
  • Evolent Health
  • HBI Solutions, Inc.
  • Health Catalyst Inc.
  • Johns Hopkins University
  • Lightbeam Health Solutions, LLC
  • Optum Inc. by UnitedHealth Group
  • Perahealth, Inc.
BJH 24.11.15

The Clinical Risk Grouping Solution Market was valued at USD 925.17 million in 2023, expected to reach USD 1,052.19 million in 2024, and is projected to grow at a CAGR of 13.82%, to USD 2,289.95 million by 2030.

The Clinical Risk Grouping Solution (CRGS) market represents a segment focused on developing sophisticated tools designed to categorize patients based on their clinical risk profiles. The primary scope of CRGS is to enhance healthcare outcomes by enabling personalized and data-driven care management. These solutions are essential in reducing medical errors, lowering healthcare costs, and improving patient outcomes by allowing providers to identify high-risk patients and tailor interventions accordingly. Applications include healthcare policy design, insurance risk assessment, and hospital resource management, with end-use spanning hospitals, insurance companies, and governmental health agencies. Market growth is primarily driven by the increasing adoption of data analytics in healthcare, growing emphasis on quality care and efficiency, and the rising complexity of patient care needs. The surge in healthcare expenditure and the regulatory push toward value-based care models further bolster demand.

KEY MARKET STATISTICS
Base Year [2023] USD 925.17 million
Estimated Year [2024] USD 1,052.19 million
Forecast Year [2030] USD 2,289.95 million
CAGR (%) 13.82%

Latest potential opportunities arise from technological advancements like AI and machine learning, which enhance the predictive accuracy and efficiency of CRGS. Market players could benefit significantly by focusing on integrating these technologies into existing solutions. Furthermore, expansion into emerging markets, fueled by the digital transformation of healthcare systems in these regions, presents another avenue of growth. However, challenges persist, such as high implementation costs, data privacy concerns, and the nuanced integration required to fit existing healthcare IT ecosystems. Moreover, resistance to change and skill gaps among healthcare professionals impede seamless adoption.

Innovation opportunities lie in developing user-friendly interfaces that require minimal training and improving interoperability standards to ensure seamless data flow across platforms. The CRGS market reflects a dynamic intersection of technology and healthcare, where continuous innovation driven by customer feedback and technological progress is essential for staying competitive. Emphasizing collaborative partnerships and staying abreast of regulatory changes will be vital for companies aiming to capitalize on this burgeoning market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Clinical Risk Grouping Solution Market

The Clinical Risk Grouping Solution Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing focus on patient's risk management
    • Implementation of big data in the healthcare industry to transform clinical outcomes
    • Advantages of risk management solutions
  • Market Restraints
    • Lack of infrastructure coupled with capital intensive clinical solutions
  • Market Opportunities
    • Increasing focus on AI and machine learning
    • Adoption of recording and maintaining the health records
    • Increasing physician burnout due to documentation needs
  • Market Challenges
    • Patient data privacy concerns

Porter's Five Forces: A Strategic Tool for Navigating the Clinical Risk Grouping Solution Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Clinical Risk Grouping Solution Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Clinical Risk Grouping Solution Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Clinical Risk Grouping Solution Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Clinical Risk Grouping Solution Market

A detailed market share analysis in the Clinical Risk Grouping Solution Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Clinical Risk Grouping Solution Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Clinical Risk Grouping Solution Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Clinical Risk Grouping Solution Market

A strategic analysis of the Clinical Risk Grouping Solution Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Clinical Risk Grouping Solution Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Conduent, Inc., Dynamic Healthcare Systems, Inc. by Reveleer, Evolent Health, HBI Solutions, Inc., Health Catalyst Inc., Johns Hopkins University, Lightbeam Health Solutions, LLC, Optum Inc. by UnitedHealth Group, and Perahealth, Inc..

Market Segmentation & Coverage

This research report categorizes the Clinical Risk Grouping Solution Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Dashboard Analytics Solutions, Risk Reporting Solutions, and Scorecards & Visualization Tools.
  • Based on Deployment Mode, market is studied across Private Cloud and Public Cloud.
  • Based on End User, market is studied across Ambulatory Care Centers, Hospitals, Long-Term Care Centers, and Payers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing focus on patient's risk management
      • 5.1.1.2. Implementation of big data in the healthcare industry to transform clinical outcomes
      • 5.1.1.3. Advantages of risk management solutions
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of infrastructure coupled with capital intensive clinical solutions
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing focus on AI and machine learning
      • 5.1.3.2. Adoption of recording and maintaining the health records
      • 5.1.3.3. Increasing physician burnout due to documentation needs
    • 5.1.4. Challenges
      • 5.1.4.1. Patient data privacy concerns
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Clinical Risk Grouping Solution Market, by Product

  • 6.1. Introduction
  • 6.2. Dashboard Analytics Solutions
  • 6.3. Risk Reporting Solutions
  • 6.4. Scorecards & Visualization Tools

7. Clinical Risk Grouping Solution Market, by Deployment Mode

  • 7.1. Introduction
  • 7.2. Private Cloud
  • 7.3. Public Cloud

8. Clinical Risk Grouping Solution Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Care Centers
  • 8.3. Hospitals
  • 8.4. Long-Term Care Centers
  • 8.5. Payers

9. Americas Clinical Risk Grouping Solution Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Clinical Risk Grouping Solution Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Clinical Risk Grouping Solution Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 3M Company
  • 2. Conduent, Inc.
  • 3. Dynamic Healthcare Systems, Inc. by Reveleer
  • 4. Evolent Health
  • 5. HBI Solutions, Inc.
  • 6. Health Catalyst Inc.
  • 7. Johns Hopkins University
  • 8. Lightbeam Health Solutions, LLC
  • 9. Optum Inc. by UnitedHealth Group
  • 10. Perahealth, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦